biostudies-literatureWang QScience and Technology Development Project of Traditional Chinese Medicine of Shandong ProvinceKey Research and Development Project of Shandong ProvinceLetter, Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineProject of National Old Traditional Chinese Medicine Expert LIU Xianghong InheritanceShandong Province ‘Taishan Scholar’ Construction Project FundsProject of National Famous and Old Traditional Chinese Medicine Expert ZHANG Hongxing Inheritance StudioLetter, National Administration of Traditional Chinese MedicineVoyaging Talent Project of Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine[Shandong Province ‘Taishan Scholar’ Construction Project Funds]Project of National Traditional Chinese Medicine Characteristic Technology Inheritance TalentLetter, National Administration of Traditional Chinese Medicine]Talent Project of Shandong University of Traditional Chinese Medicine833-852https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539401biostudies-literatureUnknown62(1)<h4>Context</h4>Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus. Chinese patent medicines (CPMs) are widely used in clinical practice to treat DPN.<h4>Objective</h4>This study aims to summarize the latest evidence on the harms and benefits of CPMs as adjunctive therapy for DPN.<h4>Materials and methods</h4>We conducted searches for randomized controlled trials (RCTs) evaluating CPMs in conjunction with mecobalamin (Mec) or alpha-lipoic acid (αLA) across eight databases up to July 2024. The surface under the cumulative ranking area (SUCRA) was utilized to assess the clinical efficacy rate (CER), the peroneal motor nerve conduction velocity (pMNCV), the peroneal sensory nerve conduction velocity (pSNCV), the median motor nerve conduction velocity (mMPharmaceutical biologyComparative efficacy and safety of Chinese patent medicines as an adjunctive therapy for diabetic peripheral neuropathy: systematic review and network meta-analysis of randomized controlled trials.PMC115394012019GNC21307ts201712097202113010823, 2017WS7092023 No. 1432022 No. 752023 No. 352019-02082023 No. 962023 No. 532022 No. 76Liu XLi YXu MWang QXie HShan LZhang HSun SWang ZHuang RXu YfalseComparative efficacy and safety of Chinese patent medicines as an adjunctive therapy for diabetic peripheral neuropathy: systematic review and network meta-analysis of randomized controlled trials.<h4>Context</h4>Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus. Chinese patent medicines (CPMs) are widely used in clinical practice to treat DPN.<h4>Objective</h4>This study aims to summarize the latest evidence on the harms and benefits of CPMs as adjunctive therapy for DPN.<h4>Materials and methods</h4>We conducted searches for randomized controlled trials (RCTs) evaluating CPMs in conjunction with mecobalamin (Mec) or alpha-lipoic acid (αLA) across eight databases up to July 2024. The surface under the cumulative ranking area (SUCRA) was utilized to assess the clinical efficacy rate (CER), the peroneal motor nerve conduction velocity (pMNCV), the peroneal sensory nerve conduction velocity (pSNCV), the median motor nerve conduction velocity (mM2024-01-01T00:00:00Z2024 Dec2025-04-21T22:35:24.922Z2025-04-05T18:49:56.604ZS-EPMC115394013949737210.1080/13880209.2024.2422084